Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProPeC: HIPEC in Locally Advanced Gastric Cancer
NCT04180761Phase 2Withdrawn
- Sponsor
- University Hospital Tübingen
- Start
- Nov 2019
- Primary completion
- Mar 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of cisplatin, doxorubicin in gastric cancer (GC), adenocarcinoma of the gastroesophageal junction, sponsored by University Hospital Tübingen. Planned start Nov 2019; status: withdrawn.
02
Drugs
cisplatindoxorubicin
03
Conditions
gastric cancer (GC)adenocarcinoma of the gastroesophageal junction
Beyond the preview
Go deeper on NCT04180761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04180761.